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involvement and with the following laboratory findings of
blood and urine examinations: BUN, creatinine, complement
component C3, and immunoglobulins. Seven cases (46.6%)
had renal involvement with microscopic haematuria (n = 4),
acute nephritic syndrome (n = 2), macroscopic haematuria
and nephrotic syndrome (n= 1).
MHC antigens were determined by tissue typing laboratory
using standard microlymphocytotoxicity assay [3]. The
relative risks for each HLA antigen for HSP were calculated
by means of ratios of study and control groups (relative
risk = (antigen + patient% x antigen — control%)/(antigen
— patient% x antigen + control%)). Confidence interval of
99% was 0.767-3.000 for these relative risk values.
In HSP patients, HLA-A3, HLA-A9, HLA-Bw35 with
relative risks higher than 99% maximum confidence limit
(3.000) showed the strongest association with HSP (Table 1).
We have been unable to find an association between MHC
antigens and the studies in first-degree relatives, because
relative risks of all antigens in each locus were below 3.000.
No common haplotype was found in both patient and
family studies.
HSP has been linked to HLA Bw35 and HLA-DR4 by
some authors, although several investigators have been
unable to find an association [1]. There has been still much
speculation on the relation between HSP and MHC antigens.
Our results agree in part with previous findings by others,
but also include differences from recent studies such as the
significance of HLA-A3 and HLA-A9.
All these observations demonstrate that disease susceptibil-
ity genes may play a role in the pathogenesis of HSP. We
have described some genetic markers for HSP in Turkish
population and tried to compare them with previous findings.
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Table 1. The relative risks of HLA antigens in Turkish children with
Henoch-SchOnlein purpura
HLA-A1 :0.9
A2 :0.4
A3 :3.6*
A9 :3.1*
A3(hl.2
A 10:0.4
B5 :1.8
B8 :1.2
B12 :1.3
B14 :1.3
B17 :1.8
B21 :1.2
Bw35:3.8*
Bw73:2.5
Bw4 :0.2
Bw6 :0.6
B7 :0.6
B13 :0.6
B40 :0.6
B27 :0.2
B37 :0.2
Cw2:1.3
Cw3:0.4
Cw4:1.5
Cw6:0.2
DR1
DR2
DR3
DR4
DR5
DR7
DR11
:0.3
:0.3
:0.6
:0.9
:0.4
:0.3
:0.2
DRw53:0.2
*99% confidence interval: 0.767-3.000.
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L-carnitine improves vascular refilling in haemodialysis
patients during ultrafiltration
Sir,
Patients on maintenance haemodialysis are reported to
exhibit disturbed carnitine metabolism and carnitine defi-
ciency [1]. There are reports that carnitine supplementation
in patients undergoing chronic haemodialysis may lead to
the amelioration of uraemic anaemia and improved exercise
tolerance. Recently carnitine was also found to reduce
the rate of intradialytic hypotensive episodes and muscle
cramps [2].
Carnitine is a peptide synthesized in liver, kidney, and
brain from the essential amino acids lysine and methionine.
It facilitates the entry of long-chain fatty acids into mitochon-
dria and therefore serves as an important metabolic cofactor.
Skeletal and cardiac muscle and the kidneys rely primarily
on fatty acids as an energy substrate. Recently it has been
hypothesized that carnitine also has a vascular mechanism
of action [3]. According to this hypothesis 'external' carnitine
plays a role in metabolic fine regulation at a cellular level by
promoting local blood flow under conditions of metabolic
stress through changes in vascular endothelial and smooth
muscle cells.
During haemodialysis excess accumulated body water is
removed from haemodialysis patients by using ultrafiltration.
During this process fluid is first removed from the vascular
compartment. There are various compensatory haemo-
dynamic mechanisms to counteract this depletion of blood
volume in order to preserve blood pressure and tissue perfu-
sion. They include decreased venous capacitance, increased
cardiac rate and contractility, and increased vascular resist-
ance. In addition a shift of fluid is initiated from the
extravascular to the vascular compartment. An imbalance
between the rate of this vascular refilling and the ultrafiltra-
tion rate can result in clinically overt hypovolaemia [4].
It has been suggested that L-carnitine might improve
tolerance to ultrafiltration. In order to study the mechanism
behind this, we measured vascular refilling during haemodia-
lysis. Ten patients undergoing maintenance haemodialysis
were studied prior to carnitine supplementation and after 4
weeks of carnitine therapy. One gram of L-carnitine was
administered i.v. after each dialysis session. All patients were
dialysed thrice weekly with high-flux dialysers, the dialysis
time being 7.5 or 9 h per week, according to the patients
Kt/V values. Eight patients were on acetate and two on
bicarbonate dialysis. All patients were normotensive at the
time of the study, and nine were on antihypertensive medica-
tion (calcium-channel blockers and/or ACE inhibitors, one
patient was on beta blockers). Patients with diabetic nephro-
pathy were excluded.
The rate constant of vascular refilling was calculated from
the change in blood volume and colloid-osmotic pressure
and was normalized for 50-kg lean body mass (Lp =
ml x min"1 x mmHg"1 x 50kg"1) [5]. The relative change in
blood volume was monitored continuously by means of
ultrasound velocity and the change in colloid-osmotic pres-
sure was calculated from plasma protein concentrations. At
the beginning of the dialysis session the patients were sub-
jected to an 'ultrafiltration pulse' for 20 min. The volume
ultrafiltered during this 'pulse' was equivalent to the neces-
sary ultrafiltration-volume per hour to reach the patients
ideal predialysis weight. After 4 weeks of carnitine
supplementation the serum free carnitine increased in all
patients from 43.6±11.3 to 149.8 ± 58.9 umol/1 (M±SD,
paired t test, P<0.02). Lp increased significantly in six of
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10 patients from 4.54±0.95 to 9.09±2.45 (M±SD,
P<0.002, paired t test). This corresponded to a mean
increase of more than 100%. In the remaining four patients
we observed a decrease in Lp of 5.62±0.56 to 3.36±1.34
(M±SD). There were no differences in pre- and post-
supplementation caraitine, other laboratory findings, blood
pressure, interdialytic weight gain, medication, and dialysis
modality between the two groups.
This study has shown that a majority (60%) of patients
have increased vascular refilling after carnitine therapy. In
selected patients L-carnitine might contribute to better ultra-
filtration tolerance during haemodialysis. This might be due
to an improved regional blood flow distribution, through its
extracellular functions apart from its role in fatty acid
metabolism [6]. These may lead to the promotion of local
blood flow and an increased vascular refilling rate. We were
unable to identify any different characteristics in the
non-responders. Further research is needed to determine the
subgroup of patients who benefit from carnitine
supplementation and whether this leads to long-term haemo-
dynamic stability on dialysis.
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